Company intelligence / Profile preview
Anji Pharma
Cambridge, Massachusetts, United Statesanjipharma.com ↗
- Ownership
- Private
- Employees
- ~9
- Development stage
- Other
01
Overview
Anji Pharma is advancing multiple clinical programs including ANJ900 in Phase 3 for Type 2 Diabetes with Kidney Disease, TTX-564 in Phase 1 for solid tumors, and BRD-810 (MCL1 inhibitor) in preclinical development.
- Therapeutic areas
- Metabolic DisordersEndocrinologyHematologyOncologyNeurologyInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Broad Institute
Beyond the preview
Go deeper on Anji Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anji Pharma.